Calidi Biotherapeutics vs Revolution Medicines
CLDI and RVMD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CLDI and RVMD compare
Revolution Medicines is the larger company, worth 23063 times as much as Calidi Biotherapeutics ($41.0B against $1.8M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CLDI | RVMD |
|---|---|---|
| Size and price | ||
| Market cap | $1.8M | $41.0B |
| Share price | $0.688 | $191.31 |
| Change, 1 year | −97.1% | 230% |
| Change, 5 years | −100.0% | 468% |
| Beta (5Y) | 0.55 | 1.35 |
| Employees | – | 883 |
| StockData Score | ||
| Total score | 3 | 3 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 0 |
| Health score | 2 | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.6× (better) | 15.7× |
| FCF yield | – | −3.0% |
| Profitability | ||
| Return on equity | −714% | −79.1% (better) |
| Financial health | ||
| Debt / equity | 0.01 | – |
| Interest coverage | −247.9× | −27.4× (better) |
| Current ratio | 1.68 | 11.38 (better) |
| Altman Z-score | −36.68 | 12.82 (better) |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | – | 105% |
| Held by insiders | 58.4% | 5.3% |
| Insider net buying, 12 months | −$1.2K (better) | −$153M |
| Superinvestors holding | – | 1 |
Go deeper
- CLDI stock overview
- CLDI income statement
- CLDI valuation and score
- RVMD stock overview
- RVMD income statement
- RVMD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.